Printer Friendly

Catalyst Biosciences says Korean MFDS approves sixth cohort of CB 2679d trial.

Catalyst Biosciences announced that the Korean Ministry of Food and Drug Safety, or MFDS, approved the addition of a sixth cohort to the Phase 1/2 trial of CB 2679d in individuals with severe hemophilia B following positive data from the multi-dose Cohort 5 that was disclosed on February 9. Cohort 6 will enroll up to five patients. Each individual will receive a single intravenous loading dose of 75 IU/kg, followed by nine daily subcutaneous doses of 150 IU/kg CB 2679d. The loading dose will be administered 30 minutes before the first subcutaneous dose. The study will be completed in South Korea in coordination with the Company's collaborator ISU Abxis.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Apr 12, 2018
Previous Article:Seattle Genetics highlights ADC technologies, immuno-oncology program at AACR.
Next Article:Pfizer initiates Phase 1b trial for DMD therapy candidate.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters